Bill. Thanks,
We the of effective adult days iron now across iron treatment only in with is X gram iron anemia receive deficiency IV very one month. broad pleased minute with on Pictured shown only of our this IDA for demonstrating that message earlier patients overarching infusion brochures Feraheme three label to eight marketing or apart. right is the to are FDA the for the Feraheme approval here X.XX
In data data the to addition versus of strong hypophosphatemia is sharing fatigue Feraheme. of use physicians the our force new our include safety label and non-inferiority efficacy Injectafer already on release the with the sales symptoms and that of
me you about Let tell more data. important this
clinical failed XX anemic studies the score scoring fatigue a a III original of were scores Phase gauges scale study called who scoring patients iron is in patients A FACIT-fatigue. At oral a the with placebo-controlled with filing. measured on trial higher of sNDA fatigue. One had symptoms severe FACIT-fatigue bad. primary fatigue. using with the submitted Fatigue XXX was baseline This of patients is system less in our indicating
chemotherapy. oncology fatigue the were In scores fact anemic they undergoing similar under patient to
feeling much the Phase significantly showing they of III non-inferiority severe So improvement which that every by and a patients were in only meaningful. Injectafer FACIT patients a fatigue. week was clearly see Feraheme can randomized have our week and you scores was our the Feraheme study study has higher After the point XX.X receiving Feraheme fatigue data that placebo five incidence study label. improved better iron treating improvement in in In patients demonstrated hypophosphatemia double-blind against than was clinically very which reported IV anemic in Injectafer. and was there was recent most it’s
with for to Injectafer. Feraheme In on both current of weeks. fact, The out phosphate contrary Feraheme the left. of chart on time five Interestingly the phosphate here less right below XX% normal are and significantly weeks levels shown levels as and chart be over five lower to receiving X% perception than compares patients range persisted the in the which in market compared the
difficult irons. well compete iron that the by we Prior label, for half we this can that And our hypophosphatemia, develop into label only So implications and Injectafer are older iron to patients can time entire And serious gives market. we have can use with due at periods for as say it’s for over clinical fair can taking IV that for prolonged to share including pain of grow fatigue. which both IV for important us We new treated be bone of risk Injectafer is physicians patients about that issues. aware this something which the differentiate now IDA the from physicians new broad being market believe to disease. from believe IV with to will treating kidney and/or the is compete the this Feraheme share more about the important Injectafer Today patients educating as muscle approval and community opportunity the Feraheme of prevention. already team market chronic should further
and a treatment Beyond expansion failing have for Many are that roughly been these on market have they there yet treated is IV million diagnosed X.X iron, IDA. big that folks on people been the opportunity with oral are into iron. with who of an not
IDA we have not label, reducing need dosing patients about helping opportunity with Feraheme the So fatigue the we an strategy, long portion. educate understand instead Thereby that access eligible them able think three-pronged physicians patients it’s contracting all continue convenient broad now suffering do When to now anemic suffer. of impact by just patients only we’re for the first, on the CKD to our to expand about and from regimen.
to and appropriate get So proposition customers ensure our value enhance for great opportunity it’s patients the the treatment. a
Feraheme label the we’re for to use. patient a XXXX benefits and lot there to differentiation. important the are causes the where therapy of sure our setting understand tone And physicians is in Being are foundation customer and places of beyond Additionally, future able types leveraging make expanding enhancing setting IDA diagnosed finally new and for enforcing today. Feraheme the is
in we Down clinics already issues as expand with such expand segments, reach patient additional GI with and can women offices bleeding have uterine we in infusion OB/GYNs road women’s the capabilities can footprint. abnormal hematology/oncology commercial with presence are a we offices our forces. the health we sales sales large We into our our existing into as with where diagnosed two towards gynecological look
Makena. Now to let’s turn
February XX, on Makena Bill March. by to we received of we mentioned, approval end subcutaneous the preparing auto-injector of As are and launch
most work back to units And Discrete no so that to the for attributes We needle nurses private IM visibility formulation. upper disrobe to – and this minute the thinner XX examiner a physicians, We to other what needle the seconds will supposed no versus ready discrete a patient free needle and/or and for in to on of It’s for pen again But as needle with important. important needle in when prevents called seconds syringe that do a injection be sticks is shows level administer of is approximately the the analysis. need length the attributes efficient, patients. in full with only has out to auto-injector data is auto-injector. and patients and it’s pen research will can It’s time comes administration a and XX to guard therefore for Choice as of worry the there right administered one if from providers friendly, the no arm them, scary important. to the were have that the the asked health the ease is things is patients these is device well that strongly that and we in a of themselves use box be care need whole private The Slide administered to. a shorter, about need administration need think of protective device And takes no emphasize use all XX, which what vials examiner.
most given subcutaneous cases intramuscular the the significant won’t In an statistically in decision. choice, it making be patient’s auto-injector the be patient physicians to for fact, it the injection. determining will compared preference In a
our primary you since the capture yesterday doesn’t difference The IM. indicated a XX% was the physicians not in world treated charts. there to intermuscular of shows Then side subcutaneous share of profile of The So a we what Makena the their left the may a think was are we seem at indication that potential conversion, the being we XX% we And show share introduced market potential market wholesale is of an saw bit report about auto-injector. who pie research this Makena subcutaneous subcu for is reason high auto-injector. expected XX%. patients commented ease physicians for that use Physicians of to shift patients XX% with received would to Makena These The compliant where be the of the no auto-injector. auto-injector. on what office more patients not the slide think? do of physicians staff also but use that only
eventually that if version can prefer available. You the was we but even comes and product. was the physicians what IM IM and that to the assume generic today, than IM auto-injector. to competitors also subcu at physicians from prescribe see not see Obviously to would compounded these the do clearly comes formulation that it generic a when share more the there This subcu expense encouraging to asked we the research of that’s formulation case Makena
a ensure the our to with activities to the becomes imperatives Medicaid auto-injector follows; auto-injector launch. way to that including as market launch ensure access are key under payers out care upon the as standard teams subcu are So of are working access
the and coming will you promotional auto-injector recall language soon contractual majority carrying the addition is availability subcu commercial of be As the way. tools. related Private highlighting auto-injector product pricing immediate of have to only
subcu to launching We the the end from converting will possible. and begin quickly market as as be auto-injector high
initially will educating office the on them benefits and getting We the front staff of be auto-injector. in of
possible. of devices Our auto-injector, field ease important to use and be on as its sensation. own administer market possibility appropriately the teams the communicate device, from Getting will to having of how as IM will nurses how using stinging HCPs and patients benefits including be to help of demonstration the the to trained device about physicians use to moving auto-injectors quickly transient including
immediate the use We care. auto-injector this to of Connection enrollment. use begin will our the for with also of injection And to work applying and possibility proactively sites team through device against alternative gives Care with expand validity Makena new and to the finally, awareness the office increase physicians new inside staff patient of
For example, would retail benefit. a nice pharmacies. be This
country, OB/GYN a For pharmacy subcu local to we’re rural might example, a easier. in whereas week the of getting difficult, the quick parts office visit be auto-injection retail every and is
the an intramuscular our with and where really approval an Registry to innovative the patients to to Cord and of injection. Blood delivery, alternative healthcare ability mode now turn excited business, with we So to providers option growth. I’ll equip we’ve returned alternative with
Our last an our important enrollments year. versus first X%, segment four were quarter business. up of time of And is quarter this four
with the A additional child customer Blood someone families and are children repeat First-time for will XX% to their they two nearly store catalysts of first time referrals. and have CBR. next sources important of have likely revenue, Cord is who likelihood
their longer efficient for fee. said of fee per upfront these of families and and to the most the that X% stored for first is model than expecting stored an enrollment attractive Blood CBR, in XXX,XXX someone Banking. and considering than revenue be contributes growth. solid ongoing positioned than an the may of revenue long-term With that and total and leading now annual with units more in two-thirds more growth. addition, business of All friends this of CBR consists that storage with likely revenue year, also second increase less collection CBR CBR circles chooses the an indicator also to has today. store is time a In Referrals date term business processing social Cord reason are is rate
in Intrarosa, Now a we symptom to and to vulvar Endoceutics is turn VVA product atrophy launched vaginal year first-in-class to treat let’s in-licensed dyspareunia, for Intrarosa and women. a the moderate or in last therapy of severe July. post-menopausal common
for not contain risk only the increase cardiovascular this Intrarosa about therapy. associated disease also estrogen a cancer, of dementia treatment It’s the box local warning only condition. In fact, is in monist in product the that does category probable and the with
has a action. differentiated Intrarosa of Additionally, mechanism
market converted androgens effective As portion women only contains that androgens decline a dyspareunia. number age, clinical quickly. cells, sex two as on facilitates currently sales, a market significant estrogens. post-menopausal of Intrarosa like of precautions of hormones made rather a the women market suffer DHEA, and this in and effect with as currently percentage about is This dyspareunia. X.X important the The discussing increasing indicated of cells, physicians providing Intrarosa. grab has the clinically in are tissue to estimated the has than the $X prescribed million annual or are allowed level, In America locally the today. in opportunity treatments synthetic a billion amount women of as existing safety There the We’ve in but considering therapy, on and focused treatment helps prescription more prasterone, levels superficial by improvements of benefit XXXX, good safe estrogens, have statistically the therapy a awareness DHA, improvement non-estrogen is well in X,XXX parabasal million pH prescribers overtime. who XX significant. physician progress time now on estrogen active to which we use significant and production Intrarosa and restore and and And women spend high who in having over vaginal the of with of from
will they they women that XXXX, nearly avoiding nothing dyspareunia, warning over-the-counter it women they be and have the our treatment year. enormous digital are safety represents be of an about unaware all. Intrarosa, will that where concerned not are issues phase our medical a condition with As lubricants efforts other her of using or to aware we box the campaign consumer and of treatments This also at is may that treatment. a estrogen-containing include the XX non-estrogen These because we is focus this enter opportunity awareness new treatable, next launch expand million
condition both campaigns and We launching new will patients option help educate treatment brand Intrarosa. be and about to unbranded their their
connecting It online directed she pain to will media like her social women information and symptoms start who The this? is with why on for are or seeing something will intercourse. how trying are to likely with woman we understand, starting we experiencing ensure So Facebook, medical do during they starts about the do by that condition.
treatable. is Our older. goals that understanding it’s the menopause a and that symptom she away is comes condition medical of dyspareunia that not getting a It’s of result
is is On will options. option she a and site, treatment there is not estrogen whether of offline, risk therapies online called person treatment for likely she’ll prescription. click and that non-estrogen, getting physician speak the on ad learn to an about pop time to a Now an new person a She’ll educational seeking and warning in in it. with her that up, associated now or Intrarosa, banner Intrarosa
this experiencing new ask who’s is about prescribed woman by Intrarosa, to itching and are a by And a XX% post-menopausal that non-estrogen there’s called for therapy dyspareunia, their For of in who drug alternative what the is? dryness, now problem physician. branded knows with name a patients
has So women, for a the condition this treatment education position the million XX non-estrogen Intrarosa and on American is option. huge reach to us new these provide opportunity
review launch our XX. Slide priorities on progress Finally, across our with details me let quickly
with physician were Our initial and patient increasing focused efforts on driving access, awareness prescribing.
number We over XXX the generated continue we’ve across salesforce will We’ve commercial speaker at to strong XXXX. approximately are programs our two-thirds physician since currently launch. that grow generated through unrestricted XX,XXX prescriptions And with country. and throughout access awareness of already
three XXXX, addition initiatives all of two. continue the with and in progress, good will So growth
focus who drive our number are the include message expanding we encouraging Intrarosa, dyspareunia. last And to of launch we just women I as the commercial treatment our will action our five, suffering now from the this from postmenopausal for suffering to new choice be growth mechanism strong transitioning option option patients of to are As view we reviewed in choice menopause. then of the slide, all will physician should safety With customers to due do be first symptoms first for efficacy dyspareunia dyspareunia the patient. Intrarosa treatment and as from now profile. educating indicated Intrarosa relieving
activity. can our forward I’ll another you over the As to Ted. throughout to progress With that, year. going I launch it turn year to busy you on updating of it’s see, Ted? look
